{{'Search' | translate}}
 

12 well tissue culture plates

Company: Sigma-Aldrich
Catalog#: 3516
Bio-protocol()
Company-protocol()
Other protocol()

A Modified Semisolid Clonal Culture for Identification of B-1 and B-2 Progenitor Colony Forming Ability of Mouse Embryonic Hemogenic Endothelial Cells
Author:
Date:
2020-05-05
[Abstract]  The search for the origin of the first hematopoietic stem cells (HSCs) in the mouse embryo has been a hot topic in the field of developmental hematopoiesis. Detecting lymphoid potential is one of the supportive evidence to show the definitive hematopoietic activity of HSCs. However, the first B-lymphoid potential in the mouse embryos are reported to be biased to innate-like B-1 cell lineage that can develop from hemogenic endothelial cells (HECs) independently of HSCs. On the other hand, conventional adaptive immune B cells (B-2) cells are considered to be exclusively derived from HSCs. Therefore, segregating B-1 and B-2 progenitor potential is important to understand the developmental process of HSCs that are also produced from HECs through intermediate precursors referred to as ... [摘要]  [摘要 ] 在搜索起源的第一造血干细胞(HSCs)在小鼠胚胎一直是一个热门话题在该领域发展造血功能。检测淋巴潜力是一个支持性证据显示权威造血活动的造血干细胞然而,据报道,小鼠胚胎中的第一个B淋巴样电位偏向于先天性B-1细胞谱系,该谱系可以从造血内皮细胞(HEC)脱离HSC发育而来。 B细胞(B-2)细胞被认为仅来自HSC。因此,分离B-1和B-2祖细胞的潜力对于理解也由HEC通过中间前体(也称为HEC)产生的HSC的发育过程非常重要。 HECs和pre-HSCs均显示pre-HSCs显示内皮表面表型并需要基质支持以检测其造血活性。利用基质细胞培养后再进行改良的半固体克隆培养的方法使我们能够检测B-1的菌落形成单位数量/ B-2祖细胞最初源自HEC / HSC之前的细胞,将反映B-1偏倚或多谱系繁殖的HSC的潜力。

[背景 ] 半固体克隆培养(甲基纤维素集落形成测定法)是检测造血祖细胞数量的传统方法。一个集落被认为是来自单个祖细胞(克隆来源),添加的细胞因子在细胞的形成中起着重要作用。产量菌落,例如Epo增强了红细胞的菌落形成单位(CFU-E)或红细胞的爆发形成单位(BFU-E),而G-CSF / GM-CSF将增强CFU-G(粒细胞),M ...

Human Endothelial Cell Spheroid-based Sprouting Angiogenesis Assay in Collagen
Author:
Date:
2018-09-05
[Abstract]  Angiogenesis, the formation of new blood vessels from pre-existing ones plays an important role during organ development, regeneration and tumor progression. The spheroid-based sprouting assay is a well-established and robust method to study the influence of genetic alterations or pharmacological compounds on capillary-like tube formation of primary cultured endothelial cells. A major advantage of this assay is the possibility to study angiogenesis in a 3D environment. Endothelial cells are cultured as hanging drops to form spheroids. Those spheroids are embedded into a collagen matrix and tube formation is analyzed 24 h later. By analyzing sprout number and sprout length the effects of genetic manipulation or drug treatment on angiogenesis can be investigated. [摘要]  血管生成,从先前存在的血管形成新血管在器官发育,再生和肿瘤进展中起重要作用。 基于球体的发芽测定法是一种成熟且稳健的方法,用于研究遗传改变或药理学化合物对原代培养的内皮细胞的毛细血管样管形成的影响。 该测定的主要优点是可以在3D环境中研究血管生成。 将内皮细胞培养为悬滴以形成球状体。 将这些球状体嵌入胶原基质中,24小时后分析管形成。 通过分析发芽数和发芽长度,可以研究遗传操作或药物治疗对血管生成的影响。

【背景】血管为器官提供氧气和营养。在不再满足局部需求的情况下,细胞分泌血管内皮生长因子(VEGF)以诱导新血管的形成。新的容器芽由一个由茎细胞牵引的前端细胞组成(Potente和Makinen,2017)。血管生成在生理条件下(例如,肌肉和脂肪组织的生长)以及病理条件(例如,伤口愈合,黄斑变性和肿瘤生长)发生。因此,非常需要破译协调血管生成的基本机制并测试干扰病理性血管生成的化合物。

基于球体的发芽试验由Thomas Korff博士和Hellmut Augustin博士在90年代后期开发(Korff和Augustin,1999),使研究人员能够快速研究药物或基因操作对发芽血管生成的影响。稳健的方式(Heiss et al。,2015)。基于球体的发芽测定的一个重要优点是分析3D环境中的芽形成。这促进内皮细胞之间的细胞 - ...

Sleeping Beauty Transposon-based System for Rapid Generation of HBV-replicating Stable Cell Lines
Author:
Date:
2018-07-05
[Abstract]  The stable HBV-transfected cell lines, which based on stable integration of replication-competent HBV genome into hepatic cells, are widely used in basic research and antiviral drug evaluation against HBV. However, previous reported strategies to generate HBV-replicating cell lines, which primarily rely on random integration of exogenous DNA by plasmid transfection, are inefficient and time-consuming. We newly developed an all-in-one Sleeping Beauty transposon system (denoted pTSMP-HBV vector) for robust generation of stable HBV-replicating cell lines of different genotype. The pTSMP-HBV vector contains HBV 1.3-copy genome and dual selection markers (mCherry and puromycin resistance gene), allowing rapid enrichment of stably-transfected cells via red fluorescence-activated cell sorting ... [摘要]  稳定的HBV转染细胞系基于将复制能力的HBV基因组稳定整合到肝细胞中,广泛用于基础研究和针对HBV的抗病毒药物评估。然而,先前报道的产生HBV复制细胞系的策略(其主要依赖于通过质粒转染的外源DNA的随机整合)是低效且耗时的。我们新开发了一体化睡眠美容转座子系统(表示为pTSMP-HBV载体),用于稳定产生不同基因型的稳定HBV复制细胞系。 pTSMP-HBV载体含有HBV1.3拷贝基因组和双重选择标记(mCherry和嘌呤霉素抗性基因),允许通过红色荧光激活细胞分选和嘌呤霉素抗生素选择快速富集稳定转染的细胞。在该方案中,我们描述了构建HBV复制稳定细胞和系统评估这些细胞的HBV复制和病毒蛋白表达谱的详细程序。

【背景】慢性乙型肝炎病毒(HBV)感染目前是一个主要的公共卫生负担,影响全球超过2.4亿人(Witt-Kehati et al。,2016)。慢性HBV患者患慢性活动性肝炎,肝硬化或原发性肝细胞癌(HCC)的风险升高(Schweitzer et al。,2015)。目前用干扰素-α或核苷类似物治疗并不能根除病毒,它们对清除乙型肝炎表面抗原(HBsAg)的作用有限(Lucifora和Protzer,2016; Soriano et al。,2017) 。因此,迫切需要开发新的抗病毒抑制剂(Nassal,2015)。

用于评估新药抗HBV活性的细胞培养模型是新药开发的重要工具。稳定的HBV复制细胞系,携带复制能力的HBV基因组稳定整合到人肝癌细胞系(Huh7和/或HepG2)的基因组中,被广泛用于评估抗病毒药物的作用(Witt-Kehati ...

Comments